New White Paper! New Strategies for Health Care Industry Convergence

Posted by Fuld + Company

Nov 23, 2015 8:00:00 AM

When setting competitive strategy in rapidly converging markets, it’s easy to miss the forest for the trees. Relying on tried and true approaches to strategy development may no longer be good enough when multiple markets collide.

Read More

Topics: Fuld + Company, Market Analysis, Scenario Analysis, Technology/Telecomm, Healthcare, Industry Convergence, Competitive Strategy

New Videos! R&D, Innovation, and Scenario Planning

Posted by Fuld + Company

Nov 12, 2015 10:26:24 AM

Are you developing R&D strategies in a vacuum? What avenues for collaboration do innovation models open up? Is consolidation a long-term solution in declining industries?

CEO and President Ken Sawka speaks with Sr. Vice President, Head of Diversified Practice Diane Borska about how uncovering competitor priorities can answer these questions.


Read More

Topics: Competitive Intelligence, War Games, Fuld + Company, Innovation, Scenario Analysis, Competitive Strategy

New Video! Business Disruption

Posted by Fuld + Company

Nov 5, 2015 1:22:38 PM

The latest wave of disruption has been driven by technology platforms, consumer experience, and the oft-cited "sharing economy."

CEO and President Ken Sawka and Founder Leonard Fuld discuss:

  • Is any market safe?
  • Are incumbents reacting in strategic ways?
  • What's the degree of customer stickiness for the likes of Uber and Airbnb? 

Video after the jump.


Read More

Topics: Competitive Intelligence, Brand Insights, Early Warning Monitoring, Fuld + Company, Fuld, Leonard, Competitive Strategy

New White Paper! Competitor Crazy Ivans

Posted by Fuld + Company

Nov 5, 2015 1:17:41 PM

What do soviet submarines, Sean Connery, and competitive intelligence have in common?

Our latest white paper Competitor Crazy Ivans reveals the connection.



Read More

Topics: Early Warning Monitoring, Fuld + Company, Competitive Strategy

New Video! What is CI?

Posted by Fuld + Company

Nov 5, 2015 1:05:48 PM

How do we reduce risks? Is our strategy flexible enough for all plausible market disruptions? What is the best timetable for our product launch? Time for CI, someone says. Yes, but...what is that?

There is a tendency to conflate CI with market research. Certainly, understanding market dynamics is key for responding to a competitor’s offering. Checking in with customers through surveys, focus groups, and social media touchstones sheds light on preferences and wish lists. For the most part, though, market research looks back, solely focused on a customer’s inclination to buy.

Competitive intelligence looks ahead, taking the long view of your category and your market. Developed with vision and intention, CI probes manufacturing, distribution, inventory, corporate structure, messaging, new entrants (those you can see and those barely visible), investment strategies, pressure points, threats, and yes, customers.

Watch CEO + President Ken Sawka and Founder Leonard Fuld discuss the definition and nature of competitive intelligence today:


Read More

Topics: Competitive Intelligence, Fuld + Company, Fuld, Leonard, Competitive Strategy

New White Paper! Millennials: Predictors of Future Disruptions

Posted by Fuld + Company

Nov 5, 2015 12:35:05 PM

If you've been following us this past summer, you'll know Fuld + Company Founder Leonard Fuld spent some of those sunny days on the Rose Fitzgerald Kennedy Greenway. He was seeking insight into the minds of millennials, the demographic that will comprise 75% of the U.S. workforce in just 10 years. How did they feel about Uber, Amazon, and Obamacare? Were they shocked by Blackberry's demise? What did they want their weddings to look like?

The five surveys he conducted are now available in one white paper, Millennials: Predictors of Future Disruptions.

Read More

Topics: Brand Insights, Innovation, Market Analysis, Fuld, Leonard, Competitive Strategy

Pfizer’s Xeljanz: An Uphill Battle

Posted by Adi Reske

Oct 28, 2015 9:32:16 AM

Approx. 6 million people in the US have plaque psoriasisOn October 14th, 2015, Pfizer announced receipt of a Complete Response Letter (CRL) from the FDA regarding its recent supplemental New Drug Application (sNDA) for Xeljanz (tofacitinib) in moderate to severe plaque psoriasis.

The FDA accepted Pfizer’s filing in February 2015 based on data from the Phase III Oral treatment Psoriasis Trials (OPT) Program. A global, multi-study, clinical development program, OPT was designed to evaluate Xeljanz 5 mg and 10 mg twice daily in patients with the skin disorder.

Read More

Topics: Brand Insights, Market Analysis, Pharma, Life Sciences, Competitive Strategy

Dell Acquires EMC: Heavy Clouds, No Rain

Posted by Ken Sawka

Oct 27, 2015 12:06:53 PM

On October 12, Dell announced its plans to acquire EMC Corporation for $67 billion
, the largest technology industry deal to date, a deal clearly intended to bolster Dell’s ability to compete in the increasingly lucrative corporate data center market. This move follows HP’s split into two organizations which itself was engineered to free HP’s enterprise business from the low-margin shackles of its consumer PC and printer business.  While the Dell-EMC deal will accelerate the transition of corporate data assets to the cloud, the new entity could face significant challenges that hamper its ability to make it rain. 

Our experience conducting war games for Global Fortune 100 companies and analyzing competition in enterprise IT has made it clear that the market is undergoing a dramatic transformation. Our analysis, conducted over an extensive period of time and involving a variety of players, demonstrates that this transformation is characterized by several confluent factors that the combined EMC-Dell will have to navigate to achieve success: 

Read More

Topics: Competitive Intelligence, War Games, Brand Insights, Market Analysis, Technology/Telecomm, Merger and Acquisition

Jack Bauer and the Flu

Posted by Robert Flynn

Oct 23, 2015 6:49:12 AM

On February 5, 2015, Public Health England announced that the flu vaccine had demonstrated low effectiveness against the main strain of flu that had circulated this past winter. Dr. Michael Skinner of Imperial College London, said in response, “Trying to predict which seasonal flu vaccine to produce each year must be a bit like a Jack Bauer car chase in Los Angeles…bound to prove somewhat hit & miss.” 

A similar miss occurred in 2004, when the United States suspended The Chiron Corporation’s shipment of 48 million doses of vaccine, citing problems at the company’s Liverpool, England, manufacturing plant.

Read More

Topics: Brand Insights, Market Analysis, Pharma, Scenario Analysis, Healthcare, Life Sciences, Merger and Acquisition

Upcoming Event: Fuld + Co. Speaking at Health Innovators' Panel Thursday

Posted by Fuld + Company

Oct 19, 2015 4:39:07 PM

Alexis Kuchins - VP, Life Sciences Business Development - joins a panel of strategists, marketers, and researchers at "Marketing Healthcare Innovations: Know Your Customer, Know Opportunity" this Thursday in Cambridge. 

Topics to be covered include: 

  • Gathering customer intelligence to guide product design and uncover value 
  • Uncovering what investors or development partner organizations are looking for 
  • Knowing your competition to better know yourself 

Read More

Topics: Events, Fuld + Company, Innovation, Healthcare

Fuld + Company Blog

The material on this page draws on the research and experience of Fuld + Company thought leaders, consultants and others. Learn more about our expertise here.

Request for Information

If you'd like someone at Fuld to contact you regarding your strategic competitive challenges, fill out the form below.